The bovine papillomavirus E5 protein and the PDGF β receptor: It takes two to tango  by Talbert-Slagle, Kristina & DiMaio, Daniel
Virology 384 (2009) 345–351
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roMinireview
The bovine papillomavirus E5 protein and the PDGF β receptor: It takes two to tango
Kristina Talbert-Slagle a, Daniel DiMaio b,c,d,⁎
a Department of Epidemiology and Public Health, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA
b Department of Genetics, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA
c Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA
d Department of Therapeutic Radiology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA⁎ Corresponding author. Department of Genetics, Yale
P.O. Box 208005, New Haven, CT 06520-8005, USA. Fax:
E-mail address: daniel.dimaio@yale.edu (D. DiMaio).
0042-6822/$ – see front matter © 2008 Elsevier Inc. Al
doi:10.1016/j.virol.2008.09.033a b s t r a c ta r t i c l e i n f oArticle history: The extremely hydrophobic
Received 5 September 2008
Accepted 30 September 2008
Available online 6 November 2008
Keywords:
Oncogene
Transmembrane protein
Tyrosine kinase
BPV E5, 44-amino acid bovine papillomavirus (BPV) E5 protein is the smallest known
oncoprotein, which orchestrates cell transformation by causing ligand-independent activation of a cellular
receptor tyrosine kinase, the platelet-derived growth factor β receptor (PDGFβR). The E5 protein forms a
dimer in transformed cells and is essentially an isolated membrane-spanning segment that binds directly to
the transmembrane domain of the PDGFβR, inducing receptor dimerization, autophosphorylation, and
sustained mitogenic signaling. There are few sequence constraints for activity as long as the overall
hydrophobicity of the E5 protein and its ability to dimerize are preserved. Nevertheless, the E5 protein is
highly speciﬁc for the PDGFβR and does not activate other cellular proteins. Genetic screens of thousands of
small, artiﬁcial hydrophobic proteins with randomized transmembrane domains inserted into an E5 scaffold
identiﬁed proteins with diverse transmembrane sequences that activate the PDGFβR, including some
activators as small as 32-amino acids. Analysis of these novel proteins has provided new insight into the
requirements for PDGFβR activation and speciﬁc transmembrane recognition in general. These results
suggest that small, transmembrane proteins can be constructed and selected that speciﬁcally bind to other
cellular or viral transmembrane target proteins. By using this approach, we have isolated a 44-amino acid
artiﬁcial transmembrane protein that appears to activate the human erythropoietin receptor. Studies of the
tiny, hydrophobic BPV E5 protein have not only revealed a novel mechanism of viral oncogenesis, but have
also suggested that it may be possible to develop artiﬁcial small proteins that speciﬁcally modulate much
larger target proteins by acting within cellular or viral membranes.
© 2008 Elsevier Inc. All rights reserved.Small DNA viruses face intense evolutionary pressure to maximize
their capacity for replication and spread while minimizing the size of
their genomes. Individual viruses utilize a variety of means to
accomplish this goal: by constructing capsids from repeating
subunits; by encoding modular proteins with biologically active
elements consisting, in some cases, of only a short stretch of amino
acids; and by translating the same segment of RNA in different reading
frames to synthesize proteins with totally different amino acid
sequences. The bovine papillomavirus type 1 (BPV) and closely related
ﬁbropapillomaviruses have perfected another strategy, namely to
encode a very small protein with potent biological activities, in order
to harness the signaling pathways of the host cell at the cost of a
miniscule fraction of the viral genome. Themajor oncogene product of
these viruses, the transmembrane E5 protein, is only 44-amino acids
long. By comparison, another well-known viral oncoprotein, SV40
large T antigen, is 708-amino acids. The E5 protein is not only the
smallest known oncoprotein, it is one of the shortest independentlyUniversity School of Medicine,
+1 203 785 6765.
l rights reserved.translated proteins known. The E5 sequence is also very hydrophobic,
resembling the membrane-spanning segment of a transmembrane
protein (Fig. 1). Despite its diminutive size and unusual composition,
the E5 protein causes tumorigenic cell transformation by strongly and
speciﬁcally activating its target, the platelet-derived growth factor β
receptor (PDGFβR), in a ligand-independentmanner. Detailed analysis
of this unique transforming protein has broader implications, as its
mechanism of engaging the cellular machinery has revealed new
principles of transmembrane protein function and suggested novel
approaches to manipulate cell phenotype. In this review, we recount
the story of BPV E5 and the PDGF β receptor, highlighting the features
that make it unique, what we have learned from it, and the potential
scientiﬁc and clinical developments it foretells.
BPV induces skin ﬁbropapillomas, or warts, in cattle. It also induces
tumors in hamsters and transforms ﬁbroblasts in tissue culture {for a
review of the history of BPV research, see (Lowy, 2007)}. Genetic
analysis of the BPV genome mapped this in vitro transformation
activity to the BPV E5 gene (Fig. 2) (Groff and Lancaster, 1986; Rabson
et al., 1986; Schiller et al., 1986; Yang et al., 1985), which encodes a 44-
amino acid, 7 kDa membrane-associated protein that exists as a dimer
in transformed mouse cells (Schlegel et al., 1986). Its very small size
Fig. 1. Predicted amino acid sequence of the BPV E5 protein (top) and proposed
transmembrane orientation of the E5 dimer (bottom).
346 Minireviewand unusual, very hydrophobic sequence suggested that the E5
protein is essentially an isolated transmembrane domain with
transforming activity. Because of this unprecedented conclusion, a
variety of in-frame and frameshift mutations were constructed in the
E5 reading frame and analyzed for their effect. The results of these
experiments revealed an absolute correlation between transforming
activity of the mutants and the existence of an intact reading frame
downstream of the putative E5 initiation codon (Burkhardt et al.,
1987; DiMaio et al., 1986). These experiments delineated the E5
coding region and conﬁrmed that this small open reading frame was
actually translated into a protein with transforming activity. These
conclusions were conﬁrmed by the demonstration that expression of
the E5 protein in the absence of other viral genes is sufﬁcient to
transform immortalized murine cells to tumorigenicity and to cause
growth transformation of primary human cells (Bergman et al., 1988;
Petti and Ray, 2000; Petti et al., 1991).
Consistent with its strongly hydrophobic amino acid composition,
including a central stretch of 29 consecutive hydrophobic amino acids
interrupted by only a glutamine at position 17, the E5 protein is found
in membrane fractions of transformed cells (Schlegel et al., 1986). It
has been localized via immunoﬂuorescence microscopy primarily to
Golgi and endoplasmic reticulum membranes, with little if any
expression at the plasma membrane (Burkhardt et al., 1989). In
bovine warts, the E5 protein is localized to basal epithelial cells and
highly differentiated keratinocytes (Burnett et al., 1992). The E5
protein appears to adopt a type II transmembrane orientation, i.e. with
its hydrophilic C-terminus extending into the lumen of the endoplas-
mic reticulum or Golgi apparatus (Burkhardt et al., 1989). Biophysical
experiments and molecular modeling indicated that the E5 protein is
in fact a transmembrane dimer that adopts a symmetric left-handed
coiled-coil conﬁguration (Oates et al., 2008; Surti et al., 1998).
The very small size of the E5 protein suggested that it would be
unlikely to tolerate many mutations and still retain biological activity.Fig. 2. The E5 protein is the major BPV oncogene in mouse ﬁbroblasts. Mouse C127 cells were
mutation that disrupts the E5 gene. Cells were stained after 2 weeks to demonstrate the apHowever, early studies demonstrated that the entire amino-terminal
one quarter of the protein could be substituted with an unrelated
sequence of hydrophobic amino acids without loss of transforming
activity (DiMaio et al., 1986). Subsequent analysis, ﬁrst employing
extensive mutagenesis of codons 15 through 25 and then complete
exchange of the central hydrophobic region of the E5 protein with
random hydrophobic sequences, further indicated that this small
protein could tolerate a surprising number of substitutions (Horwitz et
al.,1988; Horwitz et al.,1989; Kulke et al., 1992;Meyer et al.,1994). The
few required amino acids include two C-terminal cysteines important
for dimerization, the glutamine at position 17, and an aspartic acid at
position 33 (Horwitz et al.,1988). Indeed, in several cases, insertion of a
glutamine into otherwise inactive E5-like proteins containing large
blocks of random hydrophobic sequences conferred activity (Kulke
et al.,1992). These data revealed that the extremely small, hydrophobic
BPV E5 protein can exert its powerful effect on cell growth even if it
harbored numerous sequence changes, as long as the overall hydro-
phobicity of the protein and certain key residues are maintained.
Multiple cellular targets of the E5 protein have been proposed. The
epidermal growth factor receptor, colony stimulating factor-1 recep-
tor, an α-adaptin-like protein, and the 16K subunit of vacuolar H+-
ATPase have been shown to interact with the E5 protein, enhance its
biological activity in certain settings, or both (Cohen et al.,
1993a,1993b; Goldstein and Schlegel, 1990; Goldstein et al., 1991;
Martin et al., 1989). Nevertheless, extensive genetic and biochemical
data indicate that cell transformation is mediated primarily through
binding of the E5 protein to the β isoform of the endogenous PDGF
receptor, a receptor tyrosine kinase (DiMaio and Mattoon, 2001; Petti
and DiMaio, 1992; Petti et al., 1991), although alternative pathways of
transformation may also exist (Andresson et al., 1995; Suprynowicz et
al., 2002; Suprynowicz et al., 2005). The ∼1000-amino acid PDGFβR is
a single-span, type I transmembrane protein with three domains: a
large, amino-terminal extracellular domain that binds its ligand PDGF;
a short (∼20-amino acid) membrane-spanning domain; and a large,
intracellular kinase domain. Normally, PDGF binding induces dimer-
ization of the receptor, activation of the tyrosine kinase activity,
autophosphorylation of the intracellular domain of the receptor on
tyrosine, and mitogenic signaling. Genetic studies demonstrated that
the PDGFβR is essential for E5-mediated cell transformation in a
variety of cell systems, and that this activity required the kinase
activity but not the ligand binding activity of the receptor (Drum-
mond-Barbosa et al., 1995; Goldstein et al., 1994; Nilson and DiMaio,
1993; Riese and DiMaio, 1995). In addition, studies with inhibitors of
PDGFβR kinase activity and use of a repressible E5 gene demonstrated
that maintenance of transformation required sustained PDGFβR
activation (Klein et al., 1998; Lai et al., 2005).
Like PDGF, the E5 protein forms a stable complex with the PDGFβR
and induces receptor dimerization and autophosphorylation, which
allows cellular signaling proteins containing SH2 domains to bind the
receptor and initiate signaling (Figs. 3, 4) (Drummond-Barbosa et al.,
1995; Goldstein et al., 1992; Lai et al., 1998, 2000; Petti and DiMaio,transfected with no viral DNA, wild-type BPV DNA, and a BPV mutant with a frameshift
pearance of transformed foci.
Fig. 3. Activation of the PDGFβR by the E5 protein. BaF3 cells expressing the wild-type
PDGFβR, a kinase-defective receptor mutant, and a receptor truncation mutant lacking
most of the extracellular ligand binding domain were co-expressed in cells with the E5
protein (+) or an empty vector (−). Tyrosine phosphorylated PDGFβR was detected by
immunoprecipitation followed by Western blotting for phosphotyrosine. M, p, and t
indicate the position of the mature, precursor, and truncated forms of the PDGFβR,
respectively. Adapted by permission from Macmillan Publishers Ltd: Oncogene
20:7866–7873, 2001.
347Minireview1992; Petti et al., 1991, 2008). However, unlike PDGF, BPV E5 interacts
with the receptor not through the ligand binding domain of the
receptor, but through its transmembrane domain (Cohen et al., 1993a;
Drummond-Barbosa et al., 1995; Goldstein et al., 1992). Several
features of this interaction are unique to BPV E5 and are worth
emphasizing. First, activation of PDGFβR by BPV E5 occurs exclusively
through transmembrane and juxtamembrane interactions. Analysis of
receptor truncation mutants and point mutants, as well as chimeric
receptor constructs, indicated that productive interaction with the E5
protein requires the transmembrane domain of PDGFβR (Cohen et al.,
1993a; Goldstein et al., 1992; Petti et al., 1997; Staebler et al., 1995).
Furthermore, experiments with a truncated PDGFβR lacking the
extracellular domain demonstrated that E5 binds and activates the
receptor in a ligand-independent manner (Fig. 3) (Drummond-
Barbosa et al., 1995), i.e., in the absence of PDGF binding. Finally,
coimmunoprecipitation experiments showed that the E5 protein
could associate stably with a segment of the PDGFβR consisting
primarily of the transmembrane domain but lacking both the
extracellular and intracellular domains (Nappi et al., 2002).
A second noteworthy feature of the E5-PDGFβR interaction is the
requirement that the E5 protein must be a dimer to bind and activate
the PDGFβR. Mutating the C-terminal cysteines prevents formation of
the E5 dimer, inhibits association with PDGFβR, and abrogates
transforming activity (Fig. 4) (Horwitz et al., 1988; Nilson et al.,Fig. 4. The E5 protein and the PDGFR form a stable complex in cells. C127 cells
expressing the wild-type E5 protein or the indicated E5 mutants were immunopreci-
pitated by an antibody that recognizes the E5 protein and immunoblotted with an
antibody that recognizes the mature and precursor forms of the PDGFβR. Note that the
wild-type PDGFβR and several receptor mutants associate with the E5 protein, but
mutations at gln17, asp33, and the C-terminal cysteines prevent complex formation. (J.
Virology (1995) 69:5869–5874, reproduced with permission from American Society for
Microbiology.)1995). Furthermore, a heterologous dimerization domain can replace
the C-terminal cysteines in mediating transformation, unless the
domain contains a mutation that blocks dimerization (Mattoon et al.,
2001). Additional genetic experiments utilized seven chimeric E5
constructs that forced dimerization of the E5 segments in speciﬁc
orientations relative to one another, each representing one of the
possible homodimer interfaces predicted by a symmetric left-handed
coiled-coil conﬁguration. Only one conformation was capable of
inducing robust cell transformation and PDGFβR activation, corrobor-
ating the proposed structure of the E5 dimer (Mattoon et al., 2001;
Surti et al., 1998). Taken together, these data conﬁrm that dimerization
of the E5 protein in the proper orientation is required for its ability to
activate the PDGFβR.
Mutational analysis showed that only a few of the 44 wild-type
amino acids of the E5 protein are critical for PDGFβR recognition and
transforming activity. Mutations at glutamine 17 in the transmem-
brane domain and an aspartic acid residue at position 33 in the
juxtamembrane region inhibited PDGFβR binding and activation and
impaired cell transformation (Fig. 4) (Horwitz et al., 1988; Meyer et al.,
1994; Nilson et al., 1995; Sparkowski et al., 1994). In addition, as noted
above, E5 mutants can tolerate multiple hydrophobic substitutions
and retain their activity. Mutational analysis also identiﬁed a few key
PDGFβR residues that are important for interaction with E5, including
threonine 513 in themiddle of the transmembrane domain (Nappi and
Petti, 2002; Petti et al., 1997). A lysine at position 499 of the receptor,
located in the putative juxtamembrane region but presumably not
buried within the membrane, is also important for E5 binding and
transformation (Nappi and Petti, 2002; Nappi et al., 2002; Petti et al.,
1997). The essential feature of this residue appears to be its positive
charge, because substitution with the positively-charged arginine is
tolerated.
The results summarized above and molecular modeling strongly
suggest that the E5 protein and the PDGFβR contact one another
directly and that the transmembrane domains lie in an anti-parallel
orientation relative to one another (Fig. 5). Saturation mutagenesis of
E5 at position 33, an aspartic acid in the wild-type E5 protein,
demonstrated that complex formation required a negative charge at
this juxtamembrane position, corresponding to the position of a
purported salt bridge with the required positively charged juxtamem-
brane lysine at position 499 of the PDGFβR (Klein et al., 1999; Meyer
et al., 1994). In addition, only residues capable of forming hydrogen
bonds were tolerated at position 17, a glutamine inwild-type E5 (KleinFig. 5. Schematic diagram of the complex between the E5 dimer (dark cylinders) and
twomolecules of the PDGFβR (light cylinders). The twowhite parallelograms represent
the inner and outer leaﬂets of the membrane. The solid line represents the disulﬁde
bonds that stabilize the E5 dimer, and the dotted lines represent salt bridges and
hydrogen bonds mediating the association between the E5 protein and the PDGFβR, as
well as a hydrogen bond between the glutamines that stabilizes the E5 dimer. C,
cysteine; D, aspartic acid 33; K, lysine 499; Q, glutamine 17; T, threonine 513.
Fig. 6. Surface representation of the E5 dimer as determined by molecular modeling.
One face of the E5 dimer is shown. One E5 monomer in the dimer is colored dark blue
and the other red. The essential aspartic acid (pink) and glutamine (light blue) that were
contributed by different monomers on one face of the dimer are shown. Figure courtesy
of Brad Stanley and Donald Engelman.
Fig. 7. Scheme to isolate small, transmembrane proteins with transforming activity from
complex libraries. See text for details. Reprinted from J.Mol. Biol. 338, Freeman-Cook, et
al., Selection and Characterization of Small Random Transmembrane Proteins that Bind
and Activate the Platelet-derived Growth Factor β Receptor, pp. 907–920 (2004), with
permission from Elsevier.
348 Minireviewet al., 1998; Meyer et al., 1994; Sparkowski et al., 1994). The required
threonine at position 513 in the PDGFβR transmembrane domain is
situated such that it could form a hydrogen bondwith the side chain of
the amino acid at position 17 of the E5 protein. The existence of these
two pairs of essential amino acids (Asp33/Lys499 and Gln17/Thr513)
supports the model that the interaction between the transmembrane
domains of these proteins is direct and anti-parallel, given the overall
opposite transmembrane orientation of the E5 protein (type II) and
the PDGFβR (type I) (Petti et al., 1997) (Fig. 5). Furthermore, molecular
modeling of the coiled-coil E5 dimer indicates that dimerization of the
E5 protein generates two identical faces, each of which is able to bind a
monomer of PDGFβR (Surti et al., 1998). On each face of the E5 dimer,
one E5 monomer contributes the required glutamine to the PDGFβR
binding site and the other monomer contributes the aspartic acid
(Fig. 6) (Surti et al., 1998). Thus, dimerization of the two E5monomers
generates binding sites for two PDGFβRmolecules, one on each face of
the E5 dimer (Figs. 5, 6). This arrangement provides a molecular
explanation for the ﬁndings that dimerization of the E5 protein is
required for receptor binding and that binding to the E5 protein
induces dimerization of the receptor. Another model has also been
proposed, in which alternative faces of the E5 dimer mediate
oligomerization of the E5 protein, PDGFβR binding, and activation of
the PDGFβR (Adduci and Schlegel, 1999).
Another striking feature of the E5/PDGFβR interaction is its high
speciﬁcity. For many years, the membrane-spanning domains of
proteins were regarded as fairly non-speciﬁc sequences whose
primary, if not exclusive, role was to anchor proteins in the lipid
bilayer. Recently, however, it has become apparent that the trans-
membrane domains of many proteins undergo highly speciﬁc side-by-
side interactions within themembrane. This is certainly true for the E5
protein. Some single point mutations in the transmembrane domain
of the PDGFβR can prevent E5 recognition and binding (Nappi et al.,
2002; Petti et al., 1997). Furthermore, at normal levels of expression,
the E5 protein associates with the PDGFβR but not with other receptor
tyrosine kinases, although at high expression levels additional
receptors can be recognized (Goldstein et al., 1994; Petti and DiMaio,
1994). The E5 protein is not able to bind or activate the closely-related
PDGF α receptor (PDGFαR), even though both the PDGFαR and the
PDGFβR are activated by PDGF (Goldstein et al., 1994; Petti and
DiMaio, 1994). This speciﬁcity maps to the transmembrane domain of
the receptors (Staebler et al., 1995).
Although the BPV E5 protein takes viral reductionism to the
extreme, there are other examples of small, hydrophobic viralproteins. The human papillomaviruses (HPV) encode hydrophobic
E5 proteins that are about twice the size of the BPV version. The HPV
E5 proteins are involved in virus replication and transformation,
apparently by inﬂuencing the activity of the EGF receptor and possibly
the vacuolar H+-ATPase (Conrad et al., 1993; Genther-Williams et al.,
2005). Other examples include the small hydrophobic protein (SH
protein) of the paramyxoviruses and the inﬂuenza virus M2 protein,
which oligomerizes to form an ion channel and is the target of the
anti-viral drug, amantadine. It is intriguing to speculate that cells may
also encode as-yet-unrecognized small transmembrane proteins for a
variety of processes.
The studies summarized above demonstrate that the BPV E5
protein is essentially an isolated transmembrane domain capable of
speciﬁcally modulating the activity of a much larger transmembrane
protein in trans. Only a few residues in thewild-type E5 sequence have
been identiﬁed that are required for activation of the PDGFβR, and
many of these can be substituted with amino acids exhibiting similar
properties without causing a loss of function. To explore these unique
features of the E5 protein more fully, we constructed libraries
expressing artiﬁcial, small transmembrane proteins by using the
BPV E5 sequence as a scaffold and identiﬁed other proteins that
modulate PDGFβR (Freeman-Cook and DiMaio, 2005).
In these libraries, the amino- and carboxyl-terminal segments of
the E5 protein were ﬁxed (including the essential aspartic acid at
position 33), but PCR with a degenerate oligonucleotide template was
used to replace the central segment of the E5 protein with random
sequences of primarily hydrophobic amino acids. These libraries were
constructed in retrovirus vectors and encode in aggregate many
thousands or millions of small proteins, each with a different putative
transmembrane domain. These libraries were screened in murine
ﬁbroblasts for novel proteins able to induce cell transformation, as
scored by the generation of transformed foci (Fig. 7). Genes encoding
novel proteins able to induce transformation were cloned from the
transformed cells and analyzed.
If the glutamine at position 17 was ﬁxed in an otherwise
randomized transmembrane domain, approximately 10% of the library
members displayed transforming activity (Freeman-Cook et al., 2004).
As predicted, the active proteins isolated from the libraries contained
diverse transmembrane domain sequences (Fig. 8), and all of them
transformed cells by activating the PDGFβR via its transmembrane
domain, did not activate the PDGFαR, and existed as dimers. The
remarkable ease with which active proteins with diverse transmem-
brane sequences were recovered, even though a third or more of the
protein was randomized, highlights the existence of relatively few
Fig. 8. Diverse, artiﬁcial transmembrane proteins can activate the PDGFβR and
transform cells. The ﬁgure shows the sequences of the transmembrane domain of
small, transmembrane proteins that transform cells. These proteins were recovered
from libraries in which a 15-amino acid segment was randomized to primarily
hydrophobic amino acids, but the glutamine at position 17 (bold Q) was not varied. The
top line shows the transmembrane sequence of the wild-type E5 protein. Reprinted
from J. Mol. Biol. 338, Freeman-Cook, et al., Selection and Characterization of Small
Random Transmembrane Proteins that Bind and Activate the Platelet-derived Growth
Factor β Receptor, pp. 907–920 (2004), with permission from Elsevier.
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activation if the interacting pairs of hydrophilic amino acids were
retained. This conclusion was veriﬁed by the demonstration that
insertion of a simple consensus motif derived from the active library
clones was sufﬁcient to confer activity on an inactive E5-like protein
containing an otherwise monotonous polyleucine transmembrane
domain. In a second library, the entire transmembrane domain,
including position 17, was randomized, and hydrophilic amino acids
were allowed to be inserted at a low frequency at any transmembrane
position. Only 1% of the members of this library transformed cells, but
again the PDGFβR was the exclusive target (Freeman-Cook et al.,
2005). Of note, many of the active clones contained an essential
hydrophilic amino acid, primarily at position 17 or at other positions
predicted to be in the E5 homodimer interface, where they are
partially shielded from the hydrophobic lipid environment. Several
activators isolated from randomized transmembrane protein libraries
displayed speciﬁcity that differed slightly from that of wild-type E5.
For example, in contrast to the wild-type E5 protein, some of these
proteins were able to activate a PDGFβR mutant containing a
threonine to leucine mutation at position 513 in the transmembrane
domain. The altered speciﬁcity of these small transmembrane proteins
provides additional evidence that they directly contact the transmem-
brane domain of the PDGFβR.
We also constructed and screened a library that lacked hydrophilic
transmembrane amino acids and the aspartic acid at position 33. Clones
able to transformmurine ﬁbroblasts were isolated from this library at a
very low frequency, highlighting the importance of hydrophilic
interactions in PDGFβR recognition (Ptacek et al., 2007). Like the E5
protein, the active proteins lacking hydrophilic amino acids induced
transformation by speciﬁcally activating the PDGFβR. Indeed, several of
these proteins were more speciﬁc than thewild-type E5 protein, in that
they failed to activate some transmembrane mutants of PDGFβR that
were activatedby thewild-type viralprotein. This increased speciﬁcity is
presumably a consequence of the loss of the two strong hydrophilic
interactions that are essential for interaction between the wild-type E5
protein and the PDGFβR, forcing the E5 protein and the transmembrane
domain of the PDGFβR to rely on more speciﬁc packing interactions.
Strikingly, some single amino acid changes within the small transmem-
brane proteins isolated from the library had dramatic effects on which
particular PDGFβR transmembrane mutants were recognized, and
insertion of two speciﬁc hydrophobic amino acids into a protein with
a polyleucine transmembrane domain was sufﬁcient to generate a
protein that could discriminate between the PDGFβR and the PDGFαR
transmembrane domains.
Transmembrane proteins even smaller than the E5 protein can also
bind and activate the PDGFβR. A truncated, 34-amino acid E5 protein,
consisting of near wild-type sequence through residue 33 and a
cysteine at 34, which presumably forces dimerization, was still
capable of transforming cells, but its mechanism of action was not
investigated (Meyer et al., 1994). The champion so far is a 32-aminoacid transforming protein with a novel transmembrane sequence
that activated the PDGFβR, as demonstrated by conferral of growth
factor-independent cell proliferation and receptor phosphorylation.
Further experiments with chimeric receptors demonstrated that this
very small protein, like its fellow PDGFβR activators, speciﬁcally
recognized the transmembrane domain of the PDGFβR. Despite the
absence of the carboxyl-terminal cysteines in the 32-amino acid
activator, current evidence suggests that it still forms a homodimer,
presumably through hydrogen bonding and hydrophobic packing
interactions within the transmembrane segment, underscoring the
importance of homodimerization of these small, transmembrane
proteins.
The studies summarized above suggested a new approach to
modulate the activity of cellular transmembrane proteins. We
hypothesized that it might be possible to identify other small, artiﬁcial
transmembrane proteins that bind speciﬁcally to essentially any
naturally occurring transmembrane domain. To test whether libraries
based on the E5 protein encode small transmembrane proteins that
can bind to the transmembrane domain of cellular targets that are
entirely different from the PDGFβR, we searched for novel, trans-
membrane activators of the erythropoietin receptor (EPOR). Upon
binding erythropoietin, the EPOR is phosphorylated and initiates a
signaling cascade that ultimately results in the proliferation and
differentiation of red blood cell precursors. A precedent exists for
transmembrane modulation of the EPOR, namely gp55, a variant
envelope protein encoded by the Friend Erythroleukemia Virus. gp55
binds and activates the murine EPOR, resulting in unchecked red
blood cell proliferation characteristic of erythroleukemia (Li et al.,
1989). Unlike BPV E5, gp55 is a 55 kDa protein with a relatively large
extracellular domain, but transmembrane interactions between gp55
and the EPOR appear important for receptor activation (Constanti-
nescu et al., 2003; Constantinescu et al., 1999; Zon et al., 1992). By
screening a small transmembrane protein library encoding a rando-
mized, 19-amino acid transmembrane segment, we identiﬁed a 44-
amino acid protein with a novel transmembrane domain that appears
to induce activation of the human EPOR in a ligand-independent
manner. Other than its overall hydrophobicity, the sequence of the
transmembrane domain of this protein does not resemble the
transmembrane domain of gp55 or the E5 protein. Strikingly, this
protein does not activate the closely related murine EPOR, nor does it
induce transformation in cells expressing the PDGFβR. We are in the
process of determining whether this small protein, like the wild-type
E5 protein and the other proteins previously recovered from
randomized libraries, activates its target by directly interacting with
its transmembrane domain.
These results strongly suggest that small, transmembrane
proteins based on the E5 protein can be selected that speciﬁcally
recognize a variety of transmembrane proteins. If the appropriate
selections can be devised, it may also be possible to isolate small
transmembrane proteins that inhibit their targets. Indeed, an initial
isolate that activates or simply binds its target may serve as the
substrate for further mutagenesis or directed evolution to convert it
into an inhibitor. Other laboratories have modulated the activity of
cellular transmembrane proteins by expressing small proteins
containing transmembrane domains derived from naturally occur-
ring proteins (Bennasroune et al., 2004; Lofts et al., 1993). In
contrast, the approach we describe involves the construction and
selection of active transmembrane segments with no naturally-
occurring counterpart. These artiﬁcial proteins have the potential to
display favorable properties such as higher afﬁnity, greater stability,
or increased speciﬁcity than naturally occurring proteins, as we have
observed with the small transmembrane proteins that activate
PDGFβR with greater speciﬁcity than the wild-type E5 protein. The
power of genetic selection would allow the isolation of potent
transmembrane modulators that do not occur in nature, rather than
relying on an intrinsically more restricted approach, which utilizes
350 Minireviewnaturally-occurring transmembrane segments to guide the design of
active proteins.
Inmost studies, the E5 protein and related proteinswere expressed
within cells, where they can associate with their cellular membrane
targets during intracellular trafﬁcking or at the cell surface. It is also
possible to add biologically active hydrophobic peptides exogenously
to cells. A variety of small, hydrophobic peptides based on naturally
occurring transmembrane domains have been synthesized and shown
to insert into cellular membranes, where they can bind and alter the
activity of their native transmembrane protein targets {e.g., (Herbert
et al., 1999; Manolios et al., 1990; Manolios et al., 1997; Tarasova et al.,
1999)}. Artiﬁcial hydrophobic peptides that can insert into cell
membranes and exert biological activity have also been designed
based on biophysical principles or computational modeling (Yin et al.,
2007; Reshetnyak et al; 2006).
One can envision a strategy that combines the approaches described
above to develop clinically important compounds that target trans-
membraneproteins. First, genetic selection from randomized libraries of
small transmembrane proteins could be used to identify an initial,
biologically active hit containing a transmembrane sequence not found
in nature. This transmembrane modulator could be mutagenized or
optimized computationally, and then subjected to additional selection
or testing. In this manner, it may be possible to identify minimal motifs
and deﬁne essential structural features, to convert an activator into an
inhibitor (if desired), and to optimize valuable parameters such as
afﬁnity, speciﬁcity, stability, solubility, and ease of synthesis. The
optimized protein could then serve as a template for the design of
synthetic peptides or small, peptidomimetic molecules that incorporate
these essential structural features and retain biological activity in a form
that is more suitable for delivery to patients.
Targets for this sort of approach include many cellular and viral
transmembrane proteins, such as cellular receptors for awide variety of
viruses, viral fusion proteins such as inﬂuenza virus hemagglutinin, and
a vast array of cellular proteins implicated in cancer and other diseases.
Thus, studies of a bizarre oncogene from a virus that causes warts in
cattle have revealed new insights into cell transformation, receptor
function, and transmembrane domain recognition, activity, and speci-
ﬁcity. The E5 protein still has lessons to teach us, and if we are diligent
students, we may learn how to harness its unique properties to devise
new approaches to understand cells and to prevent and treat disease.
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